A new way for clinicians in England to identify potential over-prescribing of prednisolone has been developed by the NHS Business Services Authority (NHSBSA) in an effort to reduce the associated risk of adverse side effects. In a statement published on 2 December 2021 (https://media.nhsbsa.nhs.uk/news/nhs-tackles-potential-over-prescription-of-short-course-steroid) , the NHSBSA said it had worked with Guy’s and St Thomas’ NHS Foundation Trust and the Oxford Academic Health Science Network to create a dashboard that lists patients in England who have been prescribed both prednisolone and another asthma or COPD medicine during the past 12 months.
展开▼
